Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DMT210 · 1 trial · 1 indication
Change from baseline in ADSI score between Vehicle and 5% gel
| Arm | Type | Description |
|---|---|---|
| DMT210 Topical Gel | EXPERIMENTAL | DMT210 Topical Gel 5% applied to target lesion twice daily |
| Vehicle Control | PLACEBO_COMPARATOR | Topical Gel vehicle applied to target lesion twice daily |
| Name | Type | Description |
|---|---|---|
| DMT210 Topical Gel | DRUG | DMT210 Topical Aqueous Gel 5% applied twice daily |
| Vehicle Control | DRUG | Topical Vehicle Gel applied twice daily |
Inclusion Criteria: * Male or female 12 years or older * Patient has chronic, stable AD that has been present for at least 3 months with 5-35% (inclusive) BSA (Body Surface Area) of AD involvement * Patient has two analogous, Target Lesions; one lesion within each of the two Treatment Areas * Patie...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 6 | PHASE3 | Baricitinib, corticosteroid |
| AbbVie, Inc. | ABBV | 10 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 12 | PHASE3 | Abrocitinib |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof , 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
DMT210 is an investigational small molecule topical gel being developed for the treatment of atopic dermatitis, a form of eczema. It is currently in Phase 2 clinical development and has not been approved by the FDA.
DMT210 is being developed by Dermata Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol DRMA. The company is focused on dermatology treatments.
DMT210 is in Phase 2 clinical development. A Phase 2 clinical trial for the treatment of atopic dermatitis has been completed, but the drug remains investigational and has not received FDA approval.
DMT210 has been studied in one completed Phase 2 clinical trial, identified as NCT02949960, titled 'DMT210 Topical Gel in the Treatment of Atopic Dermatitis.' The trial enrolled 19 participants with atopic dermatitis in the United States.
No, DMT210 is not FDA approved. It is an investigational drug that has completed a Phase 2 clinical trial for atopic dermatitis, but it is still in clinical development and has not been approved for any use.